Atrial fibrillation and cardioembolic stoke

Minerva Cardioangiologica

Volumn 52, Issue 2, 2004, Pages 111-124

  Ferro, J M ^a,b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Atrial fibrillation; Cerebrovascular accidents; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; AMIODARONE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; COUMARIN; FLUINDIONE; HEPARIN; WARFARIN; XIMELAGATRAN;

AGE; ANAMNESIS; ANTICOAGULATION; BLEEDING; BRAIN EMBOLISM; CEREBROVASCULAR ACCIDENT; CLINICAL EXAMINATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; FAT EMBOLISM; FATALITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART VALVE PROSTHESIS; HUMAN; HYPERTENSION; LIVER TOXICITY; LOW DRUG DOSE; NEUROIMAGING; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; RHEUMATIC DISEASE; RISK FACTOR; STROKE; SYSTOLE; TRANSIENT ISCHEMIC ATTACK; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VALVULAR HEART DISEASE;

ADULT; AGE FACTORS; AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; COMORBIDITY; DIAGNOSTIC IMAGING; FIBRINOLYTIC AGENTS; HUMANS; HYPERTENSION; INTRACRANIAL EMBOLISM; MIDDLE AGED; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; WARFARIN;

EID: 2942755830     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (142)

1. Palacio S, Hart RG. Neurologic manifestations of cardiogenic embolism. An update. Neurol Clin 2002;20:179-93.
2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. for the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention. JAMA 2001;285:2370-5.
3. Peters NS, Schilling RJ, Kanagaratnam P, Markides V. Atrial fibrillation: strategies to control, combat, and cure. Lancet 2002;359:593-603.
4. Falk RH. Atrial fibrillation. N Engl J Med 2001;344:1067-78.
5. Waldo AL. Stroke prevention in atrial fibrillation. JAMA 2003;290:1093-5.
6. Hillbom M, Numminen H, Juvela S. Recent heavy drinking of alcohol and embolic stroke. Stroke 1999;30:2307-12.
7. Hart RG. Atrial fibrillation and stroke prevention. N Engl J Med 2003;349:1015-6.
8. Rodgers H, Greenaway J, Davies T, Wood R, Steen N, Thomson R. Risk factors for first-ever stroke in older people in the North East of England. A population-based study. Stroke 2004;35:7-11.
9. Wattingney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003;108:711-6.
10. Murdock DK, Rengel LR, Schlund A, Olson KJ, Kaliebe JW, Johnkoski JA et al. Stroke and atrial fibrillation following cardiac surgery. WMJ 2003;102:26-30.
11. Tsang TS, Petty GW, Barnes ME, O'Fallon WM, Bailey KR, Wiebers DO et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol 2003;42:93-100.
12. Arboix A, García-Eroles L, Massons J, Oliveres M. Predictive clinical factors of in-hospital mortality in 231 consecutive patients with cardioembolic cerebral infarction. Cerebrovasc Dis 1998;8:8-13.
13. Eriksson S-E, Olsson J-E. Survival and recurrent strokes in patients with different subtypes of stroke: a fourteen-year follow-up study. Cerebrovasc Dis 2001;12:171-80.
14. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria. Incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 2001;32:2735-40.
15. Van Horn G, Hawes A. Global aphasia without hemiparesis: a sign of embolic encephalopathy. Neurology 1982;32:403-6.
16. Tranel D, Biller J, Damasio H, Adams HP Jr, Cornell SH. Global aphasia without hemiparesis. Arch Neurol 1987;44:304-8.
17. Ferro JM. Global aphasia without hemiparesis. Neurology 1983;33:1106.
18. Hanlon RE, Lux WE, Dromerick AW. Global aphasia without hemiparesis: language profiles and lesion distribution. J Neurol Neurosurg Psychiatry 1999;66:365-9.
19. Arquizan C, Lamy C, Mas J-L. [Simultaneous supratentorial multiple cerebral infarctions]. Rev Neurol (Paris) 1997;153:748-53.
20. Ramirez-Lassepas M, Cipolle RJ, Bjork RJ, Kowitz J, Snyder BD, Weber JC et al. Can embolic stroke be diagnosed on the basis of neurologic clinical criteria? Arch Neurol 1987;44:87-9.
21. Timsit SG, Sacco RL, Mohr JP, Foulkes MA, Tatemichi TK, Woulf PA et al. Early clinical differentiation of cerebral infarction from severe atherosclerotic stenosis and cardioembolism. Stroke 1992;23:486-91.
22. Minematsu K, Yamaguchi T, Omae T. Spectacular shrinking deficit: rapid recovery from a major hemispheric syndrome by migration of an embolus. Neurology 1992;42:157-62.
23. Arboix A, Oliveres M, Massons J, Pujades R, García-Eroles L. Early differentiation of cardioembolic from atherothrombotic cerebral infarction: a multivariate analysis. Eur J Neurol 1999;6:677-83.
24. Kimura K, Minematsu K, Wada K, Yonemura K, Nakajima M. Clinical characteristics in transient ischemic attack patients with atrial fibrillation. Intern Med 2003;42:255-8.
25. Kittner SJ, Sharkness CM, Sloan MA, Price TR, Dambrosia JM, Tuhrim S et al. Infarcts with a cardiac source of embolism in the NINDS Stroke Data Bank: neurologic examination. Neurology 1992;42:299-302.
26. Silverman IE, Restrepo L, Mathews GC. Poststroke seizures. Arch Neurol 2002;59:195-202.
27. Ay H, Oliveira-Filho J, Buonanno FS, Ezzeddine M, Schaefer PW, Rordorf G et al. Diffusion-weighted imaging identifies a subset of lacunar infarction associated with embolic source. Stroke 1990;30:2644-50.
28. Moulin T, Crepin-Leblond T, Chopard JL, Bogousslavsky J. Hemorrhagic infarcts. Eur Neurol 1993;34:64-77.
29. Jörgensen L, Torvik A. Ischaemic cerebrovascular diseases in an autopsy series 2. Prevalence, location, pathogenesis and clinical course of cerebral infarcts. J Neurol Sci 1969;9:285-320.
30. Fisher CM, Adams RD. Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. J Neuropathol Exp Neurol 1951;10:92-3.
31. de Freitas GR, Carruzzo A, Tsiskaridze A, Lobrinus JA, Bogousslavsky J. Massive haemorrhagic transformation in cardioembolic stroke: the role of arterial wall trauma and dissection. J Neurol Neurosurg Psychiatry 2001;70:672-4.
32. Molina CA, Montaner J, Abilleira S, Ibarra B, Romero F, Arenillas JF et al. Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke. Stroke 2001;32:1079-84.
33. Alexandrov AV, Black SE, Ehrlich LE, Caldwell CB, Norris JW. Predictors of hemorrhagic transformation occurring spontaneously and on anticoagulants in patients with acute ischemic stroke. Stroke 1997;28:1198-202.
34. Nighoghossian N, Hermier M, Adeleine P, Blanc Lasserre K, Derex L, Honnorat J et al. Old microbleeds are a potential risk factor for cerebral bleeding after ischemic stroke: a gradient-echo T2* - weighted brain MRI study. Stroke 2002;33:735-42.
35. Kimura K, Yasaka M, Minematsu K, Wada K, Uchino M, Yonemura K et al. Oscillating thromboemboli within the extracranial internal carotid artery demonstrated by ultrasonography in patients with acute cardioembolic stroke. Ultrasound Med Biol 1998;24:1121-4.
36. Batista P, Oliveira V, Ferro JM. The detection of microembolic signals in patients at risk of recurrent cardioembolic stroke: possible therapeutic relevance. Cerebrovasc Dis 1999;9:314-9.
37. Kelley RE, Berger JR, Alter M, Kovacs AG. Cerebral ischemia and atrial fibrillation: prospective study. Neurology 1984;34:1285-91.
38. Weinberger J, Rothlauf E, Materese E, Halperin J. Noninvasive evaluation of the extracranial carotid arteries in patients with cerebrovascular events and atrial fibrillations. Arch Intern Med 1988;148:1785-8.
39. Horning CR, Will R, Dorndorf W. Ischemic stroke and atrial fibrillation-clinics, CT, prognosis. Stroke 1989;20:138.
40. Bogousslavsky J, van Melle G, Regli F, Kappenberger L. Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne stroke registry. Neurology 1990;40:1046-50.
41. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC et al. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12.
42. Kanter MC, Tegeler CH, Pearce LA, Weinberger J, Feinberg WM, Anderson DC et al. Carotid stenosis in patients with atrial fibrillation. Prevelence, risk factors, and relationship to stroke in the Stroke Prevention in Atrial Fibrillation Study. Arch Int Med 1994;154:1372-7.
43. Van Latum JC, Koudstaal PJ, Venables GS, van Gijn J, Kappelle LJ, Algra A. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with non-rheumatic atrial fibrillation. Stroke 1995;26:801-6.
44. Ruivo A, Lopes M, Melo TP, Salgado AV, Oliveira V, Canhão P et al. Carotid stenosis associated with atrial fibrillation. Rev Neurol (Barc) 1996;24:55-8.
45. Heinzlef O, Cohen A, Amarenco P. [Atherosclerotic aortic plaques and risk of embolic stroke]. Rev Neurol (Paris) 2001;157:619-31.
46. Blackshear JL, Pearce LA, Hart RG, Zabalgoitia M, Labovitz A, Asinger RW et al. for the Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Aortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implications. Stroke 1999;30:834-40.
47. Sen S, Wu K, McNamara R, Lima J, Piantadosi S, Oppenheimer SM. Distribution, severity and risk factors for aortic atherosclerosis in cerebral ischemia. Cerebrovascular Dis 2000;10:102-9.
48. Yamanouchi H, Mizutani T, Matsushita S, Esaki Y. Paroxysmal atrial fibrillation: high frequency of embolic brain infarction in elderly autopsy patients. Neurology 1997;49:1691-4.
49. Rem JA, Hachinski VC, Boughner DR, Barnett HJ. Value of cardiac monitoring and echocardiography in TIA and stroke patients. Stroke 1985;16:950-6.
50. Come PC, Riley MF, Bivas NK. Roles of echocardiography and arrhythmia monitoring in the evaluation of patients with suspected systemic embolism. Ann Neurol 1983;13:527-31.
51. Vandenberg B, Biller J. Cardiac evaluation of the patient with stroke. Cerebrovasc Dis 1991;1 Suppl 1:73-82.
52. Berthet K, Lavergne T, Cohen A, Guize L, Bousser MG, Le Heuzey JY et al. Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke 2000;31:398-403.
53. Kouakam O, Guedon-Moreau L, Lucas C, Zghal N, Mahe I, Klug D et al. Long-term evaluation of autonomic tone in patients below 50 years of age with unexplained cerebral infarction: relation to atrial vulnerability. Europace 2000;2:297-303.
54. Barthelemy JC, Feasson-Gerard S, Garnier P, Gaspoz JM, Da Costa A, Michle D et al. Automatic cardiac events recorders reveal paroxysmal atrial fibrillation after unexplained strokes or transient ischemic attacks. Ann Noninvasive Electrocardiol 2003;8:194-9.
55. Glotzer Tv, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R et al.; MOST Investigators. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 2003;107:1614-9.
56. Hamer ME, Blumenthal JA, McCarthy EA, Phillips BG, Pritchett EL. Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am J Cardiol 1994;74:826-9.
57. Good DC, Frank S, Verhulst S, Sharma B. Cardiac abnormalities in stroke patients with negative arteriograms. Stroke 1986;1:6-11.
58. McNamara RL, Lima JAC, Whelton PK, Powe NR. Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: a cost-effectiveness analysis. Ann Int Med 1997;127:775-87.
59. Stoddard MF, Singh P, Dawn B, Longaker RA. Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. Am Heart J 2003;145:676-82.
60. Ohyama H, Hosomi N, Takahashi T, Mizushige K, Osaka K, Kohno M et al. Comparison of magnetic resonance imaging and transesophageal echocardiography in detection of thrombus in the left atrial appendage. Stroke 2003;34:2436-9.
61. Lechat PH, Mas JL, Lascault G, Loron PH, Theard M, Klimczac M et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988;318:1148-52.
62. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW et al. for the Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344:1411-20.
63. Silverman DI, Manning WJ. Strategies for cardioversion of atrial fibrillation: time for a change? N Engl J Med 2001;344:1468-9.
64. Cooper JM, Katcher MS, Orlov MV. Implantable devices for the treatment of atrial fibrillation. N Engl J Med 2002;346;2062-8.
65. Krittayaphong R, Raungrattanaamporn O, Bhuripanyo K, Sriratanasathavorn C, Pooranawattanakul S, Punlee K et al. A randomized trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. J Med Assoc Thai 2003;86 Suppl 1:S8-S16.
66. Cox JL, Ad N, Palazzo T, Fitzpatrick S, Suyderhoud JP, DeGroot KW et al. Current status of the Maze procedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg 2000;12:15-9.
67. Melo J, Adragão P, Neves J, Ferreira M, Pinto MM, Rebocho MJ et al. Surgery for atrial fibrillation using radiofrequency catheter ablation: assessment of results at one year. Eur J Cardiothorac Surg 1999;15:851-4.
68. Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Eng J Med 1998;339:659-66.
69. Sievert H, Lesh MD, Trepels T, Omran H, Bartorelli A, Della Bella P et al. Percutaneous left atrial appendage transcathether occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002;105:1887-9.
70. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation)
71. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
72. Wyse DG. Rhythm versus rate control in atrial fibrillation. J Cardiovasc Electrophysiol 2003;14:S35-9.
73. Hagens V, Van Gelder IC, Crijns HJ. for The Rate Control Versus Electrical Cardioversion of Persistent Atrial Fibrillation (RACE) Study Group. The RACE study in perspective of randomized studies on management of persistent atrial fibrillation. Card Electrophysiol Rev 2003;7:118-21.
74. Mathew JP, Parks R, Savino JS, Friedman AS, Koch C, Mangano DT et al. Atrial fibrillation following coronary artery bypass graft surgery: predictors, outcomes, and resource utilization. MultiCenter Study of Perioperative Ischemia Research Group. JAMA 1996;276:300-6.
75. Taylor GJ, Malik SA, Colliver JA, Dove JT, Moses HW, Mikell FL et al. Usefulness of atrial fibrillation as a predictor of stroke after isolated coronary artery bypass grafting. Am J Cardiol 1987;60:905-7.
76. Giri S, White CM, Dunn AB, Felton K, Freeman-Bosco L, Reddy P et al. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression (AFIST): a randomised placebo-controlled trial. Lancet 2001;357:830-6.
77. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. CHEST 1998;114:579S-9S.
78. Go AS, Hylek EM, Phillips KA, Borowsky LH, Henault LE, Chang Y et al. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation. The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2000;102:11-3.
79. Wanag TJ, Masaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. The Framaingham Heart Study. JAMA 2003;290:1049-56.
80. Van Walraven C, Hart RG, Wells G, Peterson, Koudstaal PJ, Gullov AL et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003;163:936-43.
81. EAFT Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
82. Segal JB, McNamara RL, Miller MR, Powe NR, Goodman SN, Robinson KA et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. (Cochrane Review). In: The Cochrane Library, Issue 4, 2001. Oxford: Update Software.
83. Koudstaal PJ. Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2001;(1):CD001938.
84. Hart RG, Pearce LA, Miller VT, Anderson DC, Rothrock JF, Albers GW et al. on behalf of the SPAF Investigators. Cardioembolic vs noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis 2000;10:39-43.
85. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R et al. for the Stroke Prevention in Atrial Fibrillation Investigators. Lessons from the Stroke Prevention in Atrial Fibrillation Trials. Ann Intern Med 2003;138:831-8.
86. Van Walraven C, Hart RG, Singer DE, Laupacis A, Connoly S, Peterson P et al. Oral anticoagulants vs aspirin in non-valvular atrial fibrillation. An individual patient meta-analysis. JAMA 2002;288:2441-8.
87. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6.
88. The European Atrial Fibrillation Trial study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995;333:5-10.
89. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120;897-902.
90. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulation therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-7.
91. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology 1999;53:1319-27.
92. Smith EE, Rosand J, Knudsen KA, Hylek EM, Greenberg SM. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology 2002;59:193-7.
93. Singer DE, Hylek EM. Optimal oral anticoagulation for patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995;333:1504.
94. Benavente O, Hart R, Koudstaal P, Laupacis A, McBride R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2000;(2):CD001927.
95. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26.
96. Crowther MA, Julian J, McCarty D, Douketis J, Kovacs M, Biagoni L et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000;356:1551-3.
97. Schulman S. Care of patients receiving long-term anticoagulation therapy. N Engl J Med 2003;349:675-83.
98. Blackshear JL, Zabalgoitia M, Pennock G, Fenster P, Strauss R, Halperin J et al. on behalf of the SPAF TEE investigators. Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. Am J Cardiol 1999;83:453-5.
99. White RH, McBurnie MA, Manolio T, Furberg CD, Gardin JM, Kittner SJ et al. Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. Am J Med 1999;106:165-71.
100. Evans A, Kalra L. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? Arch Intern Med 2001;161:1443-7.
101. Frykman V, Beerman B, Ryden L, Rosenqvist M. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J 2001;22:1954-9.
102. McCormick D, Gurwitz JH, Goldberg RJ, Becker R, Tate JP, Elwell A et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001;161:2458-63.
103. Scott PA, Pancioli AM, Davis LA, Frederiksen SM, Eckman J. Prevalence of atrial fibrillation and antithrombotic prophylaxis in emergency department patients. Stroke 2002;33:2664-9.
104. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999;131:927-34.
105. Deplanque D, Corea F, Arquizan C, Parnetti L, Mas J-L, Gallai V et al. Safe I Study Investigators. Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? Heart 1999;82:563-9.
106. Deplanque D, Leys D, Parnetti L, Schmidt R, Ferro J, De Reuck J et al.; and the SAFE II Investigators. Stroke prevention and atrial fibrillation: reasons leading to a inappropriate management. Main results of the SAFE II study. [In press] 2004.
107. Son-Hing MM, Laupacis A. Anticoagulant-related bleeding in older patients with atrial fibrillation. Physicians' fears often unfounded. Arch Inter Med 2003;163:1580-6.
108. Devereaux PJ, Anderson DR, Gardner MJ, Putman W, Flowerdew GJ, Brownell BF et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001;323:1218-22.
109. Lechat P, Lardoux H, Mallet A, Sanchez P, Derumeaux G, Lecompte T et al. for the FFAACS Investigators. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibriliation. Cerebrovasc Dis 2001;12:245-52.
110. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996;348:633-8.
111. Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J et al. Fixed mini-dose warfarin and aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation; Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study (the AFASAK2 study). Arch Intern Med 1998;158:1513-21.
112. Olson SB, Executive Steering committee on behalf of the SPORTIF III investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-8.
113. Eriksson BI, Bergqvist D, Kälebo P, Dahl OE, Lindbratt S, Bylock A et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II reandomised trial. Lancet 2002;360:1441-7.
114. Halperin JL; Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics, (SPORTIF III and V). Am Heart J 2003;146:431-8.
115. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997;349:1569-81.
116. Moroney JT, Bagiella E, Paik MC, Sacco RL, Desmond DW. Risk factors for early recurrence after ischemic stroke. Stroke 1998;29:2118-21.
117. Easton JD, Sherman DG. Management of cerebral embolism of cardiac origin. Stroke 1980;11:433-42.
118. Yatsu FM, Hart RG, Mohr JP, Grotta JC. Anticoagulation of embolic strokes of cardiac origin: an update. Neurology 1988;38:314-6.
119. Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy. Analysis of randomized clinical trials. Stroke 2002;33:2722-7.
120. Arboix A, García-Eroles, Oliveres M, Massons JB, Targa C. Clinical predictors of early embolic recurrence in presumed cardioembolic stroke. Cerebrovasc Dis 1998;8:345-53.
121. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: a randomized trial. Stroke 1983;14:668-76.
122. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in acute embolic stroke trial. Lancet 2000;355:1205-10.
123. Bath PMW, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D et al. for the TAIST investigators. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001;358:702-10.
124. The Publications Committee for the trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke. JAMA 1998;279:1265-72.
125. Hommel M, for the FISS bis Investigators Group. Fraxiparine in Ischaemic Stroke Study (FISS bis). Cerebrovasc Dis 1998;8:19.
126. Adams HP. Emergent use of anticoagulation for treatment of patients with ischemic stroke. Stroke 2002;33:856-61.
127. Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaturvedi S et al. Anticoagulants and antiplatelet agents in acute ischemic stroke. Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association). Neurology 2002;59:13-22.
128. Bath PMW, Iddenden R, Bath FJ. Low-molecular-weight heparins and heparinoids in acute ischemic stroke. A meta-analysis of randomized controlled trials. Stroke 2000;31:1770-8.
129. Gubitz G, Counsell C, Sandercock P, Signorini D. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Ev 2000;(2):CD000024.
130. Bath P, Leonardi-Bee J, Bath F. Low molecular weight heparin versus aspirin for acute ischaemic stroke: a systematic review. J Stroke Cerebrovasc Dis [In press].
131. Chamorro A, Vila N, Ascaso C, Blanc R. Heparin in acute stroke with atrial fibrillation. Clinical relevance of very early treatment. Arch Neurol 1999;56:1098-102.
132. American Stroke Association. 28th International Stroke Conference, February 13-15, 2003, Phoenix, AR. Rapid Anticoagulation Preventing Ischemic Damage (RAPID) Clinical Trial. Stroke 2002;33:1734-5.
133. The National Institutes of Neurological Disorders, and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
134. Yamagushi T, Hayakawa T, Kiuchi H. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke Cerebrovasc Dis 1999;3:269-72.
135. Chimowitz M, Arbor A, Pessin M, Furlan A, Wolpert S, Del Zoppo G. The effect of source of cerebral embolus on susceptibility to thrombolysis Neurology 1994;44 Suppl 2:A356.
136. Urbach H, Hartmann A, Pohl C, Omran H, Wilhelm K, Flacke S et al. Local intra-arterial thrombolysis in the carotid territory: does recanalization depend on the thromboembolus type? Neuroradiology 2002;44:695-9.
137. Phan TG, Koh M, Wijdicks EFM. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Arch Neurol 2000;57:1710-3.
138. Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke 2003;34:1710-6.
139. Blacker DJ, Wijdicks EF, McClelland RL. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology 2003;14:964-8.
140. Cromheecke ME, Levi M, Colly LP, de Mol BJ, Prins MH, Hutten BA et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet 2000;356:97-102.
141. Hohnloser SH, Connolly SJ. Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. J Cardiovasc Electrophysiol 2003;14 (9 suppl):S60-3.
142. Crystal E, Lamy A, Connoly SJ, Kleine P, Hohnloser SH, Semelhago L et al. Left Atrial Appendage Occlusion Study. Left atrial appendage study (LAAOS): a randomised clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. Am Heart J 2003;145:174-8.